# Safety and Efficacy of Generic Sofosbuvir and Ribavirin for Treatment-naive Genotype 2 Chronic Hepatitis C

> **NCT03453346** · NA · COMPLETED · sponsor: **Kawin Technology Share-holding Co., Ltd.** · enrollment: 136 (actual)

## Conditions studied

- Hepatitis C, Chronic
- Hepatitis C Virus Infection, Response to Therapy of

## Interventions

- **DRUG:** Sofosbuvir
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT03453346
- **Lead sponsor:** Kawin Technology Share-holding Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-05
- **Primary completion:** 2017-03-18
- **Final completion:** 2017-03-30
- **Target enrollment:** 136 (ACTUAL)
- **Last updated:** 2018-03-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03453346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03453346, "Safety and Efficacy of Generic Sofosbuvir and Ribavirin for Treatment-naive Genotype 2 Chronic Hepatitis C". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03453346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*